卡格列净联合阿卡波糖对2型糖尿病患者miR-144、NLRP3 mRNA及MCP-1水平的影响  

Effect of canagliflozin combined with acarbose on levels of miR-144,NLRP3 mRNA and MCP-1 in patients with type 2 diabetes mellitus

作　　者：苏海玉[1] 张宏颖[1] 杨俐[1] 张广颖[2] SU Haiyu;ZHANG Hongying;YANG Li;ZHANG Guangying(Department of Endocrinology,Langfang Municipal People′s Hospital,Langfang,Hebei 065000,China;Physical Examination Center,Langfang Municipal People′s Hospital,Langfang,Hebei 065000,China)

机构地区：[1]河北省廊坊市人民医院内分泌科,河北廊坊065000 [2]河北省廊坊市人民医院体检中心,河北廊坊065000

出　　处：《国际检验医学杂志》2022年第4期420-423,427,共5页International Journal of Laboratory Medicine

基　　金：河北省医学科学研究课题计划(20201594)。

摘　　要：目的探讨卡格列净联合阿卡波糖对2型糖尿病患者微小RNA(miR)-144、NOD样受体3炎性小体(NLRP3)mRNA及单核细胞趋化蛋白-1(MCP-1)水平的影响。方法选取2019年7月至2020年7月该院收治的2型糖尿病患者186例,依据随机数字表法分为单药治疗组、联合治疗组,每组93例。比较两组患者治疗前后血糖、胰岛素、炎症因子、miR-144、NLRP3 mRNA及MCP-1水平及治疗效果。结果与单药治疗组比较,联合治疗组治疗后餐后2 h血糖、空腹血糖、糖化血红蛋白水平更低(P<0.05),治疗后两组餐后2 h胰岛素、空腹胰岛素水平比较,差异无统计学意义(P>0.05)。治疗后,两组血清白细胞介素(IL)-1β、IL-17A、IL-23水平降低,联合治疗组血清IL-1β、IL-17A、IL-23水平低于单药治疗组(P<0.05)。与单药治疗组比较,治疗后联合治疗组血清miR-144、NLRP3 mRNA及MCP-1水平降低(P<0.05)。联合治疗组治疗有效率高于单药治疗组(P<0.05)。结论采用卡格列净联合阿卡波糖对2型糖尿病患者进行治疗,可降低患者血糖,改善胰岛素抵抗,有效性好。Objective To investigate the effect of canagliflozin combined with acarbose on the levels of miR-144,NOD like receptor 3 inflammatory corpuscle(NLRP3)mRNA and monocyte chemoattractant protein-1(MCP-1)in the patients with type 2 diabetes mellitus(T2DM).Methods A total of one hundred and eighty-six patients with T2DM in this hospital from July 2019 to July 2020 were selected and divided into the single drug treatment group and combined treatment group according to the random number table method,93 cases in each group.The levels of blood glucose,insulin,inflammatory factors,miR-144,NLRP3 mRNA,MCP-1 before and after treatment and the treatment effect were compared between the two groups.Results Compared with the single drug treatment group,the levels of postprandial 2 h blood glucose(PBG),fasting blood glucose(FPG)and glycosylated hemoglobin(HbA1c)in the combined treatment group were lower(P<0.05).After treatment,the differences of the levels of postprandial 2 h blood glucose and fasting insulin(FINS)in the two groups were not statistically significant(P>0.05).After treatment,the levels of serum interleukin(IL)-1β,IL-17A and IL-23 in the two groups were decreased,the levels of serum IL-1β,IL-17A and IL-23 in the combined treatment group were lower than those in the single drug treatment group(P<0.05).Compared with the single drug treatment group,the levels of serum miR-144,NLRP3 mRNA and MCP-1 after treatment in the combined treatment group were decreased(P<0.05).The treatment effective rate in the combined treatment group was higher than that in the single drug treatment group(P<0.05).Conclusion Adopting canagliflozin combined with acarbose treatment in the patients with T2DM is beneficial to decrease blood glucose,improve the insulin resistance,and has a good efficacy.

关 键 词：卡格列净 阿卡波糖 2型糖尿病 NOD样受体3炎性小体 单核细胞趋化蛋白-1 

分 类 号：R587.1[医药卫生—内分泌]